IRVINE, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, Vaseem Mahboob, Chief Financial Officer, and Bob Mitchell, President, are scheduled to participate at two investor conferences in December. The first conference is the 27th Annual Piper Jaffray Healthcare Conference in New York City.
|Event:||27th Annual Piper Jaffray Healthcare Conference|
|Date:||Wednesday, December 2, 2015|
|Time:||9:30 am ET|
|Participant:||John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer|
The second conference is the Oppenheimer 26th Annual Healthcare Conference in New York City.
|Event:||Oppenheimer 26th Annual Healthcare Conference|
|Date:||Tuesday, December 8, 2015|
|Time:||3:55 pm ET|
|Participant:||Bob Mitchell, President|
An audio webcast of the Company's presentations at these conferences will be available by visiting the investor relations section of Endologix's website at www.endologix.com. A replay of the presentation will be available for 30 days.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S.
CONTACT: COMPANY CONTACT: Endologix, Inc. John McDermott, CEO Vaseem Mahboob, CFO (949) 595-7200 www.endologix.com INVESTOR CONTACTS: The Ruth Group Nick Laudico (646) 536-7030 Zack Kubow (646) 536-7020Source:Endologix